Center-Authored Papers

Filters: Author is Schweizer, Michael T  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
S
Schweizer MT, Yu EY.  2015.  Persistent androgen receptor addiction in castration-resistant prostate cancer.. Journal of hematology & oncology. 8(1):128. Abstract
Schweizer MT, Antonarakis ES, Wang H, Ajiboye SA, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA et al..  2015.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.. Science translational medicine. 7(269):269ra2. Abstract
Schweizer MT, Yu EY.  2017.  AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.. Cancers. 9(1) Abstract
Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen MD, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA et al..  2016.  Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: Results from the phase II BATMAN study.. The Prostate. 76(13):1218-1226. Abstract
Schweizer MT, Antonarakis ES, Denmeade SR.  2017.  Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.. European urology. Abstract
Schweizer MT, Yu EY.  2016.  Targeting intratumoral androgens: statins and beyond.. Therapeutic advances in medical oncology. 8(5):388-95. Abstract
Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery BR, Yu EY, Cheng HH.  2016.  Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer.. Medical oncology (Northwood, London, England). 33(7):77. Abstract
Schweizer MT, Antonarakis ES.  2015.  Liquid biopsy: Clues on prostate cancer drug resistance.. Science translational medicine. 7(312):312fs45. Abstract
Schweizer MT, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Nelson PS, Yu EY, Montgomery B et al..  2016.  Mismatch repair deficiency may be common in ductal adenocarcinoma of the prostate.. Oncotarget. Abstract
M
Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.  2015.  Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.. The Prostate. 75(15):1814-20. Abstract
G
Guedes L, Antonarakis ES, Schweizer MT, Mirkheshti N, Almutairi F, Park JC, Glavaris SA, Hicks JL, Eisenberger MA, De Marzo AM et al..  2017.  MSH2 Loss in Primary Prostate Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research. Abstract
Graham L, Schweizer MT.  2016.  Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.. Medical oncology (Northwood, London, England). 33(5):44. Abstract
C
Chi EA, Schweizer MT.  2017.  Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor.. Clinical genitourinary cancer.
Cheng HH, Klemfuss N, Montgomery B, Higano CS, Schweizer MT, Mostaghel EA, McFerrin LG, Yu EY, Nelson PS, Pritchard CC.  2016.  A pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling.. The Prostate. Abstract